Good evening :)
$
₹
Innate Pharma

Innate Pharma

IPHA

NASDAQ
Asset Logo

Innate Pharma

IPHA

NASDAQ
$1.870.37% (-0.00)
$
₹
$1.870.37% (-0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $217.8M the stock is ranked 4205

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

20.09
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.64
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 3 analysts' reports

Buy
2 analysts
Hold
1 analyst
Sell
0 analyst

Analysts expect a +256.51% price upside over the next year

Current Price$1.87
Target Price$6.66

Company Profile

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
70.48
70.48
1Y Return
16.62%
16.62%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
24.45
24.45
1Y Return
34.41%
34.41%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
22.78%
22.78%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.76
30.76
1Y Return
29.71%
29.71%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.97
19.97
1Y Return
37.71%
37.71%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Innate Pharma -20.09-
AbbVie Inc70.4850.450.35
Amgen Inc24.4518.181.89

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

0.2
-24.7
4.8
-21.3
-2
-27.6
-2
-27.6
Q1 2025
Q2 2025
Q4 2025
Q1 2026
Revenue
Net Income
Financial YearQ2 2023Q3 2023Q4 2023Q1 2024Q2 2024Q4 2024Q1 2025Q2 2025Q4 2025Q1 2026
Total Revenue35.3410.7221.4416.5512.34-0.274.86-2.07-2.07
Net Income1.71-4.64-9.28-9.28-24.76--24.70-21.34-27.62-27.62
Net Profit Margin4.86%-43.31%-43.31%-56.09%-200.59%--8951.81%-439.17%1332.70%1332.70%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Innate Pharma (IPHA) share price today is $1.87 as of September 12, 2026 at 1:30 AM IST. The stock touched a day high of $1.92 and a day low of $1.87.

  2. Innate Pharma stock trades on NASDAQ under the ticker symbol IPHA.

  3. Innate Pharma's market capitalization is $217.81M as of September 12, 2026 at 1:30 AM IST.

  4. Innate Pharma's price-to-earnings (P/E) ratio is N/A as of September 11, 2026.

  5. Innate Pharma's price-to-book (P/B) ratio is 20.09 as of September 11, 2026.

  6. Yes, You can buy Innate Pharma shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Innate Pharma shares in three steps: 1. Search Innate Pharma on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Innate Pharma trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Innate Pharma (IPHA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 5.339 shares at the current price of $1.87.

Loading...